Get the Stockscreener App
5.58
3.46%
-0.20
After Hours:
5.62
0.04
+0.72%
Anteris Technologies Global Corp stock is traded at $5.58, with a volume of 72,014.
It is down -3.46% in the last 24 hours and up +0.00% over the past month.
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing innovative medical devices designed to improve the quality of life for patients with aortic stenosis. Its lead product, the DurAVR THV system, represents a unique product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.
See More
Previous Close:
$5.78
Open:
$5.7
24h Volume:
72,014
Relative Volume:
5.33
Market Cap:
$200.54M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.55
$5.7459
1-Week Range:
$5.40
$5.90
52-Week Range:
$5.40
$5.90
Anteris Technologies Global Corp Stock (AVR) Company Profile
Name
Anteris Technologies Global Corp
Sector
Industry
Phone
-
Address
-
Compare AVR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVR
Anteris Technologies Global Corp
|
5.58 | 200.54M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
114.23 | 198.13B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
364.60 | 138.99B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
88.95 | 131.10B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
81.03 | 103.90B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
74.81 | 44.12B | 6.60B | 4.16B | 490.10M | 6.93 |
Anteris Technologies Global Corp Stock (AVR) Latest News
Anteris Technologies’ Bold Shift to U.S. Markets - MSN
Admedus Limited to Relocate Corporate Services Functions to Brisbane; Announces Executive Changes - Marketscreener.com
Admedus Ltd : Admedus's CardioCel® Cleared for Sale in the US - Marketscreener.com
Anteris Technologies Redeems Convertible Notes - TipRanks
Anteris Technologies Announces New Director Appointment - TipRanks
Anteris Technologies Debuts on NASDAQ with IPO - MSN
Anteris Technologies Prepares for Stock Market Expansion - MSN
Anteris Completes Key Animal Study for EFS Submission - Marketscreener.com
Allied Healthcare Group Ltd : Allied reports no calcification from phase II CardioCel patients after 5 years - Marketscreener.com
Anteris Technologies Ltd Provides Data Update on First in Human Study of DurAVR THV Presented At New York Valves 2024 - Marketscreener.com
Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston - Marketscreener.com
Admedus Limited Appoints Maja Mcguire as Company Secretary - Marketscreener.com
Anteris Submits Confidential Draft Registration Statement for Proposed US IPO - Marketscreener.com
Anteris Technologies Ltd Reports Successful Interim Results for the First-In-Human Trial - Marketscreener.com
Admedus Limited Announces Management Changes - Marketscreener.com
Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering - Marketscreener.com
Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study - Marketscreener.com
Anteris Technologies CEO talks A$35 million raise and 2023 milestones - Marketscreener.com
Anteris Technologies closes USD 88.8M US IPO - Medical Buyer
Anteris Technologies Completes $89 Million US IPO; to list CDIs on ASX; Shares Fall 15% - Marketscreener.com
Anteris Technologies Advances with SEC Filing - TipRanks
Anteris Technologies Completes $88.8M NASDAQ IPO for Revolutionary Heart Valve Development - StockTitan
Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering - Business Wire
AVRAnteris Technologies Global Corp. Latest Stock News & Market Updates - StockTitan
Anteris Technologies Expands with U.S. IPO and Innovations - TipRanks
Anteris re-domiciliation finalised: shares trading on ASX and Nasdaq - Proactive Investors UK
Anteris Technologies goes public in U.S. - Minneapolis / St. Paul Business Journal
New Nasdaq Debut! - Jomfruland.net
Anteris Technologies Updates Bylaws to Enhance Governance - TipRanks
Anteris Technologies’ Strategic Move to the US - TipRanks
Anteris Technologies Launches New Equity Incentive Plan - TipRanks
Anteris Technologies Lists on Nasdaq Following IPO - TipRanks
Anteris Technologies lists on Nasdaq with IPO set at US$6.00 per share - Proactive Investors USA
Australian medtech Anteris stock slides 8% after $89M IPO - MSN
BTC Speciality Health Pty Ltd agreed to acquire Hospital Infusion Business from Admedus Limited. - Marketscreener.com
Admedus Limited announced that it has received AUD 6 million in funding - Marketscreener.com
U.S. IPO Weekly Recap: ServiceTitan Shines In 3 IPO Week - Seeking Alpha
Anteris Technologies Launches U.S. IPO on Nasdaq - TipRanks
Admedus : announces Placement and Rights Issue - Marketscreener.com
Anteris Technologies Ltd announced that it expects to receive funding from Mercer Street Capital Partners, LLC - Marketscreener.com
Anteris Technologies prices IPO at $6 per share (Pending:AVR) - Seeking Alpha
Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering - Yahoo Finance
Anteris Technologies Prices $88.8M Nasdaq IPO for Revolutionary Heart Valve Development - StockTitan
Allied Healthcare Group Ltd. Announces Board Changes - Marketscreener.com
Anteris Technologies Ltd Announces Fda Approves Early Feasibility Study for DurAVR THV System - Marketscreener.com
Anteris Technologies Secures US Patent for Transcatheter Heart Valve; Shares Rise 4% - Marketscreener.com
Anteris Technologies Ltd Provides Update on First In Human DurAVR THV Study - Marketscreener.com
Anteris Technologies Announces Research Partnership with Yale University and Ycrg - Marketscreener.com
Anteris Technologies Ltd Overnight Presents 30-Day Clinical Data for Full Cohort of 13 Patients Implanted with DurAVR THV During Its First-In-Human Trial - Marketscreener.com
Anteris Technologies Ltd Presents "DurAVR transcatheter aortic valve first-in- human study: impact of novel leaflet design" at the annual PCR London Valves 2022, 27-29 November 2022 - Marketscreener.com
Anteris Technologies Ltd Announces Formal Results of A Comparative Study to Investigate Aortic Flow Physiology by Cardiac MRI in Five Patients Who Received A DurAVR Transcatheter Aortic Valve (First- In-Human) - Marketscreener.com
Anteris Technologies Global Corp Stock (AVR) Financials Data
There is no financial data for Anteris Technologies Global Corp (AVR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):